Holen Sie sich die Stockscreener-App
25.50
1.07%
-0.2652
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$25.77
Offen:
$26
24-Stunden-Volumen:
31.18M
Relative Volume:
0.47
Marktkapitalisierung:
$144.87B
Einnahmen:
$62.79B
Nettoeinkommen (Verlust:
$9.84B
KGV:
14.87
EPS:
1.7156
Netto-Cashflow:
$10.38B
1W Leistung:
+1.37%
1M Leistung:
+4.36%
6M Leistung:
+6.36%
1J Leistung:
-2.32%
1-Tages-Spanne:
$25.13
$26.13
1-Wochen-Bereich:
$25.13
$26.19
52-Wochen-Spanne:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.48 | 146.52B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
989.68 | 892.86B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
201.14 | 485.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
224.00 | 394.34B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
131.91 | 249.77B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
97.38 | 245.55B | 63.90B | 19.05B | 13.05B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer’s Appetite for More Obesity Meds Leads to $150M Deal for Oral GLP-1 Drug From China - MedCity News
Pfizer Expands Obesity Pipeline With Up to $2.1 Billion Deal for YaoPharma Pill - TradingView
Pfizer signs license deal with Fosun unit for obesity drug - The Detroit News
Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs. - Barron's
Pfizer dips into China for another try at an obesity pill - BioPharma Dive
Pfizer partners with YaoPharma to develop weight management drug - Reuters
Eli Lilly's (LLY) Orforglipron Compared to Pfizer's New Collaboration - GuruFocus
Pfizer: The Most Powerful Drug Pipeline In Pharma Could Deliver Major Long-Term Gains (NYSE:PFE) - Seeking Alpha
Pfizer in pact with Fosun Pharma for oral GLP-1s (PFE:NYSE) - Seeking Alpha
Pfizer gains another obesity asset with $2bn deal for YaoPharma’s GLP-1RA - Yahoo Finance
Pfizer Signs License Deal With Fosun Unit for Obesity Drug - Bloomberg.com
State Street Corp Cuts Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer stock rating reiterated at Buy by Guggenheim on strategic moves - Investing.com Canada
Pfizer Enters Collaboration, License Agreement With YaoPharma for Weight Loss Treatment - marketscreener.com
Pfizer enters $2.1 billion deal with YaoPharma for GLP-1 obesity drug By Investing.com - Investing.com South Africa
Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement - The Manila Times
Pfizer enters $2.1 billion deal with YaoPharma for GLP-1 obesity drug - Investing.com Australia
Pfizer (PFE) Secures Global Agreement for GLP-1 Agonist Developm - GuruFocus
Pfizer Inks About $2 Bln Exclusive Deal With Fosun's YaoPharma To For Novel GLP-1 Obesity Therapy - Nasdaq
Pfizer, YaoPharma enter obesity drug collab deal - breakingthenews.net
Pfizer partners with China's YaoPharma for weight loss drug; shares up - TradingView
Pfizer partners with YaoPharma for weight management treatment - marketscreener.com
Pfizer enters into exclusive collaboration and license agreement with Yaopharma - marketscreener.com
Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma - Business Wire
Fosun Pharmaceutical says unit signs licensing agreement with Pfizer - marketscreener.com
Pfizer Inc. $PFE Shares Sold by Gabelli Funds LLC - MarketBeat
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri - GlobeNewswire Inc.
2 companies poised to capitalize on the rise of GLP-1 drugs - Morningstar Australia
Pfizer (PFE) Stock: AI Cost-Cutting and Strong Dividend Attract Investors - parameter.io
How Do Investors Really Feel About Pfizer Inc? - Benzinga
Natixis Has $45.97 Million Stock Holdings in Pfizer Inc. $PFE - MarketBeat
SVB Wealth LLC Invests $4.07 Million in Pfizer Inc. $PFE - MarketBeat
Pfizer Says Hympavzi Reduced Bleeds by 93% Compared With On-Demand Treatment in Phase-3 Study - marketscreener.com
Ossiam Boosts Stock Position in Pfizer Inc. $PFE - MarketBeat
StoneX Group Inc. Lowers Holdings in Pfizer Inc. $PFE - MarketBeat
Gamco Investors INC. ET AL Trims Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Eli Lilly, Pfizer Feature in China's Commercial Insurance Innovative Drug Catalog - marketscreener.com
Pfizer (PFE) Reports Positive Phase 3 Results for Hemophilia Tre - GuruFocus
Pfizer’s HYMPAVZI shows superior bleeding control in hemophilia phase 3 study (PFE:NYSE) - Seeking Alpha
Eli Lilly, Pfizer Land on China’s First Private Insurance List - Bloomberg.com
Pfizer (PFE) Reports Positive Phase 3 Study Results for HYMPAVZI - GuruFocus
Eli Lilly, Pfizer drugs added to China's first private insurance list - Business Standard
Ophthalmic Drugs Market Size to Cross USD 62.74 Billion by 2032, Driven by Advances in Eye Care Treatments and Rising Global Vision Disorders - GlobeNewswire Inc.
Pfizer (PFE) Stock; Rises on Strong Dividend Yield and Low Valuation Debate - CoinCentral
Federated Hermes Inc. Raises Stock Position in Pfizer Inc. $PFE - MarketBeat
California Public Employees Retirement System Has $368.78 Million Stock Position in Pfizer Inc. $PFE - MarketBeat
Eli Lilly, Pfizer land on China’s first private insurance list - The Edge Malaysia
Eli Lilly, Pfizer Secure Inclusion in Chinese Private Health Insurance Catalog - marketscreener.com
Pfizer Inc. Presents Results from the Phase 3 BASIS Study Evaluating HYMPAVZI for Adults and Adolescents - marketscreener.com
Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue - Yahoo Finance
Peptide Therapeutics Market Size to Reach USD 82.19 Billion by 2032; Surging Requirements for Targeted Medicines in Oncology Augment Market Expansion - GlobeNewswire Inc.
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):